Through a combination of research and acquisitions, Ligand has created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.
Captisol® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).Licensing Contact
Four OmniAb® therapeutic antibody platforms, OmniRat®, OmniFlic®, OmniMouse® and OmniChicken™, that produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity.Licensing Contact
The SUREtechnology Platform™, a Selexis, SA technology, is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. Several programs acquired by Ligand are based on this technology.